30 articles, transcripts, and reports
After dominating the cystic fibrosis market for quite some time, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is currently expanding its clinical programs to other diseases. While…
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q4 2020 earnings call dated Feb. 01, 2021 Corporate Participants: Michael Partridge — Senior Vice President of Investor Relations Reshma Kewalramani — Chief Executive…
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported fourth quarter 2020 earnings results today. Total revenues increased 15% year-over-year to $1.62 billion. GAAP net income was up…
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q2 2020 earnings call dated July 30, 2020 Corporate Participants: Michael Partridge — Senior Vice President, Investor Relations Reshma Kewalramani — Chief Executive Officer,…
Vertex Pharmaceuticals Inc (VRTX) Q1 2020 earnings call dated Apr. 29, 2020 Corporate Participants: Michael Partridge — Senior Vice President of Investor Relations Reshma Kewalramani — Chief Executive Officer…
Vertex Pharmaceuticals (Nasdaq: VRTX) today reported first quarter financial results for the period ended March 31, 2020. On GAAP basis, first quarter EPS was $2.29…
Biotechnology is the one industry that has been showing signs of improvement in the COVID-19 affected market. This week a bunch of biotech companies is…
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) continues to be in the luxury of escaping from the COVID-19 pandemic crisis. The stock reflected the comfort of the…
— Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported earnings of $1.70 per share in the fourth-quarter 2019, vs. $1.20 per share expected. — Total revenue rose 63% to…
— Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected — Total revenue grew 21% to $949.8…
